Technical Analysis for BBIO - BridgeBio Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Historical BBIO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Oversold Stochastic | Weakness | 0.71% | |
| Oversold Stochastic | Weakness | 1.02% | |
| Slingshot Bearish | Bearish Swing Setup | -0.43% | |
| Stochastic Buy Signal | Bullish | -0.43% | |
| Pocket Pivot | Bullish Swing Setup | -0.43% | |
| Wide Bands | Range Expansion | -0.43% | |
| Oversold Stochastic | Weakness | -0.43% | |
| Slingshot Bearish | Bearish Swing Setup | 1.67% | |
| Pocket Pivot | Bullish Swing Setup | 1.67% | |
| Outside Day | Range Expansion | 1.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 12 hours ago |
| 60 Minute Opening Range Breakout | about 14 hours ago |
| Rose Above 10 DMA | about 14 hours ago |
| Up 1% | about 15 hours ago |
| 10 DMA Resistance | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/17/2021
BridgeBio Pharma, Inc. Description
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Organ Systems Anatomy Tyrosine Kinase Tyrosine Kinase Receptors Amyloid Hyperplasia Myopathy Amyloidosis Protein Kinase Inhibitor Cardiomyopathy Fibroblast Growth Factor Receptor Transthyretin Congenital Adrenal Hyperplasia Familial Amyloid Polyneuropathy Polyneuropathy Achondroplasia TTR Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 73.5 |
| 52 Week Low | 26.17 |
| Average Volume | 848,192 |
| 200-Day Moving Average | 48.68 |
| 50-Day Moving Average | 63.67 |
| 20-Day Moving Average | 58.63 |
| 10-Day Moving Average | 55.63 |
| Average True Range | 3.21 |
| ADX | 18.27 |
| +DI | 17.25 |
| -DI | 23.18 |
| Chandelier Exit (Long, 3 ATRs ) | 61.37 |
| Chandelier Exit (Short, 3 ATRs ) | 62.58 |
| Upper Bollinger Band | 66.53 |
| Lower Bollinger Band | 50.73 |
| Percent B (%b) | 0.3 |
| BandWidth | 26.95 |
| MACD Line | -2.67 |
| MACD Signal Line | -2.52 |
| MACD Histogram | -0.1497 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 58.24 | ||||
| Resistance 3 (R3) | 58.17 | 57.19 | 57.79 | ||
| Resistance 2 (R2) | 57.19 | 56.49 | 57.23 | 57.63 | |
| Resistance 1 (R1) | 56.35 | 56.07 | 56.77 | 56.42 | 57.48 |
| Pivot Point | 55.37 | 55.37 | 55.58 | 55.41 | 55.37 |
| Support 1 (S1) | 54.53 | 54.67 | 54.95 | 54.60 | 53.54 |
| Support 2 (S2) | 53.55 | 54.25 | 53.59 | 53.39 | |
| Support 3 (S3) | 52.71 | 53.55 | 53.24 | ||
| Support 4 (S4) | 52.78 |
